Company Profile
Cellectar Biosciences Stock Price, News & Analysis
- Ticker:
- CLRB
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Cellectar Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
2.50 USD (-2.72%)
Close
Last updated: June 23, 2026 at 00:00
19.98M USD
Market cap
Why the stock is moving
CLRB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Cellectar Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cellectar Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Cellectar Biosciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Cellectar Biosciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Source: Cellectar Biosciences
- 03
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
Source: Cellectar Biosciences
- 04
- 05
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Source: Cellectar Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cellectar Biosciences (CLRB)?
Cellectar Biosciences (CLRB) most recently closed at 2.50 USD, a -2.72% move versus the previous session.
What is the market cap of Cellectar Biosciences (CLRB)?
Cellectar Biosciences currently has a market capitalization of 19.98M USD on BioPharmSignal.
What does Cellectar Biosciences do?
Cellectar Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is CLRB stock listed?
Cellectar Biosciences (CLRB) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Cellectar Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Cellectar?
Cellectar Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Cellectar Biosciences targeting with Cellectar?
Cellectar Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Biosciences?
Cellectar Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.